EC Healthcare : expects sales volume for the third quarter of FY23 to rise by no less than 8% Y-o-Y

EC Healthcare Expects Sales Volume to Increase no less than 24% YoY to no less than

HK$3.8 billion for FY23

Medical Services Sales Volume to Increase no less than 39% YoY

The Return of Mainland Visitors Brings a Positive Impact on Business Performance

EC Healthcare is pleased to announce that the Group expects sales volume for the year ended 31 March 2023 (the "Period") to increase by no less than 24% as compared with the same period last year.

The Board expects to record overall sales volume of no less than HK$3.8 billion for the Period, representing a no less than 24% YoY increase. The Group expects to achieve a no less than 39% YoY increase for medical services sales volume. Sales volume of aesthetic medical and beauty and wellness services in Hong Kong and Macau increased by no less than 24% YoY, while sales volume of aesthetic medical and beauty and wellness services in Mainland China declined by no more than 25% YoY during the Period. The decrease in aesthetic medical and beauty and wellness services was mainly due to the recurrent outbreaks of COVID-19 and the strict pandemic prevention policies. The sales volume of other services increased by no less than 36% YoY.

Mr. Eddy Tang, Chairman, Executive Director and Chief Executive Officer of EC Healthcare said, "The Group is pleased to see the Mainland visitors started to return on a gradual basis after boarder reopening. Benefiting from the return of Mainland tourists, the Group's Sales Volume contributed by Mainland visitors in Hong Kong during January to March in 2023 was approximately HK$82 million. We expect the return of Mainland visitors to continue at a gradual pace with an ongoing positive impact on our performance in Hong Kong."

- End -

EC Healthcare Expects Sales Volume to Increase no less than 24% YoY to no less than HK$3.8 billion for FY23 28 April 2023, Page 2

About EC Healthcare

EC Healthcare is Hong Kong's largest non-hospital medical service provider*, leveraging its core businesses of preventive and precision medicine, and committed to developing medical artificial intelligence by integrating its multi-disciplinary medical services. The move, which is supported by the Group's high-end branding and quality customer services, is aimed at offering customers safe and effective healthcare and medical services with professionalism. The Group is a constituent stock of the Hang Seng Composite Index and the MSCI Hong Kong Small Cap Index.

The Group principally engages in the provision of one-stop medical and health care services in Greater China. The Group provides a full range of services and products under its well-known brands, including those of its one-stop aesthetic medical solutions provider DR REBORN which has ranked first in Hong Kong by sales for years, a professional hair care center HAIR FOREST, primary care clinics jointly established with health management centre re:HEALTH, a vaccine centre Hong Kong Professional Vaccine HKPV, General outpatient clinic Tencent Doctorwork, the largest one-stop pain management centre in Hong Kong New York Medical Group, the comprehensive dental centres Bayley & Jackson Dental Surgeons, EC DENTAL CARE and Health and Care Dental Clinic, an advanced diagnostic and imaging centre HKAI, an oncology treatment centre reVIVE, a day procedure centre HKMED, a specialty clinic PREMIER MEDICAL CENTRE, SPECIALISTS CENTRAL and NEW MEDICAL CENTER, a paediatric centre PRIME CARE, a gynaecology specialist ZENITH MEDICAL CENTER AND PRENATAL DIAGNOSIS CENTRE, PathLab Medical Laboratories, Ophthalmology Center VIVID EYE and EC Veterinary Hospital and Imaging Center.

*According to independent research conducted by Frost and Sullivan in terms of revenue in 2020 and 2021